ArticleCancer research2013
Common single-nucleotide polymorphisms in the estrogen receptor β promoter are associated with colorectal cancer survival in postmenopausal women.
Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Observational
- The Influence of ESR2 Gene Polymorphisms on Susceptibility to Hepatitis B Virus-Related Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma.Biochemical genetics · 2024Article
- ERβ and Inflammation.Advances in experimental medicine and biology · 2022Article
- Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases.International journal of molecular sciences · 2021Review
- Sexual dimorphism in solid and hematological malignancies.Seminars in immunopathology · 2019Review
- Sexual dimorphism in hepatitis B and C and hepatocellular carcinoma.Seminars in immunopathology · 2019Review
- Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer.The pharmacogenomics journal · 2017Article
- Polymorphisms in the estrogen receptor alpha gene (ESR1), daily cycling estrogen and mammographic density phenotypes.BMC cancer · 2016Article
- Association of estrogen and progesterone receptor gene polymorphisms and their respective hormones in uterine leiomyomas.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Sexual dimorphism in cancer.Nature reviews. Cancer · 2016Review
- Delay discounting, genetic sensitivity, and leukocyte telomere length.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Estrogen receptor beta as target for colorectal cancer prevention.Cancer letters · 2016Review
- Estrogen receptors and their implications in colorectal carcinogenesis.Frontiers in oncology · 2015Review
- Gene variations in oestrogen pathways, CYP19A1, daily 17β-estradiol and mammographic density phenotypes in premenopausal women.Breast cancer research : BCR · 2014Article
- Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study.BMC cancer · 2014Article
- Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Genetic variations in colorectal cancer risk and clinical outcome.World journal of gastroenterology · 2014Review
- No association between germline variation in catechol-O-methyltransferase and colorectal cancer survival in postmenopausal women.Menopause (New York, N.Y.) · 2014Article
- PELP1 suppression inhibits colorectal cancer through c-Src downregulation.Oxidative medicine and cellular longevity · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Loss of estrogen receptor β (ERβ) expression in the gut is associated with colorectal cancer (CRC) initiation and progression. Germline single-nucleotide polymorphisms (SNP) in genes for the sex-steroid hormone receptors are not strongly associated with CRC risk; however, these SNPs have not previously been evaluated in relation to survival after diagnosis. We enrolled 729 women, ages 50 to 74, diagnosed with invasive CRC between 1997 and 2002 in 13 counties covered by the Seattle-Puget Sound Surveillance Epidemiology and End Results cancer registry. Participants provided germline DNA. We selected 99 tag-SNPs for the androgen receptor (AR), ERα (ESR1), ERβ (ESR2), and progesterone receptor (PGR) genes. Mortality outcomes were ascertained from the National Death Index. During a median of 6.6 years of follow-up, 244 deaths occurred (161 from CRC). We identified 20 SNPs (12 of ESR2 and 8 of PGR) for replication in 1,729 women diagnosed with incident invasive CRC (555 deaths; 405 from CRC) from three prospective cohort studies that participate in the Genetics and Epidemiology of Colorectal Cancer Consortium. Three correlated SNPs in the promoter of ESR2 (rs2987983, rs3020443, and rs2978381) were statistically significant predictors of CRC-specific and overall survival. Minor alleles of each were associated with improved survival [for rs2987983, CRC-specific HR, 0.77; 95% confidence interval (CI), 0.60-0.99 in the initial study, and HR, 0.79; CI, 0.64-0.98 in replication]. No associations were noted for SNPs of AR, ESR1, or PGR. SNPs in the promoter of ESR2 may be important to pathways related to the association between ERβ and tumor progression and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.